Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 6/20 | 0.74 |
| ▸ | AKT1 | P31749 | 3/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 9/20 | 0.49 |
| ▸ | MYLK4 | Q86YV6 | 7/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SCN1A | P35498 | 1/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3019496 | 0.86 | AKT2 (0.54) | AKT2AKT1ROCK1CHRM2SLC6A2 | |
| SCHEMBL1978044 | 0.86 | AKT2 (1.00) | AKT2AKT1ROCK1MYLK4CHRNB2 | |
| SCHEMBL3030209 | 0.85 | AKT2 (0.53) | AKT2AKT1ROCK1MYLK4CHRM2 | |
| SCHEMBL1978482 | 0.84 | CHRM2 (0.67) | AKT2ROCK1CHRM2SLC6A2SLC6A4 | |
| SCHEMBL3014453 | 0.83 | AKT2 (0.64) | AKT2AKT1ROCK1MYLK4 | |
| SCHEMBL3024656 | 0.79 | AKT2 (0.56) | AKT2AKT1ROCK1MYLK4 | |
| SCHEMBL1422822 | 0.79 | SLC6A2 (0.59) | CHRNB2CHRNA4CHRM2SLC6A2SLC6A4 | |
| SCHEMBL27511961 | 0.79 | SLC6A2 (0.59) | CHRNB2CHRNA4CHRM2SLC6A2SLC6A4 | |
| SCHEMBL2066147 | 0.79 | SLC6A2 (0.59) | CHRNB2CHRNA4CHRM2SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL7927468 | 0.77 | SLC6A2 (0.57) | CHRNB2CHRNA4CHRM2SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-08-19 | — | — | US | disclosed |
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-08-19 | — | — | US | disclosed |
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ERBB2, ABL1, GRK2 | AKT2 88/4885AKT1 73/4885ROCK1 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.